BioCentury
ARTICLE | Financial News

Adamas, HCR in $100M royalty deal

May 11, 2017 11:13 PM UTC

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) is to receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners. The company is to receive $35 million up front and $65 million upon FDA approval of ADS-5102, its candidate to treat dyskinesia in Parkinson's disease. The therapy's PDUFA date is Aug. 24.

Adamas said it will use the funds to commercialize ADS-5102, an oral extended-release formulation of amantadine, and further develop its pipeline. It has completed a Phase I study of ADS-4101, an extended-release formulation of the anticonvulsant lacosamide, which targets collapsin response mediator protein-2 (DPYSL2; CRMP-2)...